Approximately 25 years ago, our team initiated studies to determine whether outcome results from a large medical record database would yield valid results. We utilized the data in the United Kingdom (UK) General Practice Research Database (GPRD) to replicate the randomized controlled trial (RCT) study result and compared them to confirm the database results. The initial studies compared favorably, but some subsequent studies did not. This prompted development of a new strategy to determine and correct for unrecognized confounding in the database. This strategy divided outcome rates prior to initiation of therapy in the database study (which should include both identified and unidentified confounders) into the outcome rates during the treatment interval. When they differed from Cox-adjusted results, it reflected unrecognized confounding. We The study used the data from our previous observational study. It demonstrates that estrogen therapy markedly reduced death in post-menopausal women.
be applied to enable learning from such databases. Work to advance such methodologies is essential to advancing the scientific integrity Core Value underpinning learning health systems (LHSs). Indeed, in the absence of such efforts to develop and refine methodologies for learning trustworthy lessons from real-world data, we risk inadvertently creating mis-learning systems.
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The benefits of hormonal therapy for menopausal women have been debated for decades. The health benefits of hormonal therapy have been hypothesized, refuted, and re-hypothesized. The risk and benefits for specific outcomes such as cardiovascular disease, cancer, or osteoporosis are often contradictory. However, despite the large amount of data on this subject, we are not able to evaluate mortality.
The Women's Health Initiative (WHI) was a large and important randomized controlled trial (RCT) study. Subgroup analysis of the WHI RCT provided a hint that combined estrogen-progestin (EPT) therapy or estrogen (ET) therapy itself might decrease mortality in younger women (ages 50-60). [1] [2] [3] However, these results did not achieve statistical significance. Furthermore, secondary subgroup analysis could be distorted by unrecognized confounding, because subgroup analysis is similar to an observational study rather than an RCT.
Our prior observational studies that replicated the WHI RCT using the United Kingdom (UK) General Practice Research Database (GPRD) database also found a decrease in mortality with both ET and EPT therapy in women ages 50-54 and 55-79. [4] [5] [6] [7] Other outcomes in these studies could be corrected for unrecognized confounding by a new technique we developed called Prior Event Rate Ratio (PERR). 8, 9 PERR analysis is a tool to identify and quantitate unrecognized confounding for many outcomes; it involves analysis of outcomes in the time period preceding the therapy period and is then applied to the data during the analytic period. However, this strategy could not be applied to mortality (which cannot be a prior event). Therefore, we could not conclude with certainty that mortality was reduced.
Recently, we published new studies, which suggest that a strategy similar to PERR appears to overcome unrecognized confounding for mortality. 10 In Volume PTERR analysis applies an approach analogous to PERR analysis but, for the post-treatment period, permitting the study of the death outcome. As part of our process for applying these methods, the WHI replication studies were included in these studies, and this manuscript expands upon these findings. This work and its implications will subsequently be further discussed.
Beyond the specific findings, our work also serves to advance the 
| METHODS
The initial database replications of the WHI RCT included subjects from ages 50 to 79 years old. First exposed subjects were selected from those that met the entry criteria for the RCT and were being treated with either conjugated estrogen and progestin (norgestrel) if 2 of 5they had an intact uterus or no progestin if they had a prior hysterectomy. Start time for the exposed subjects was defined by when therapy began during a predetermined recruitment interval.
Then the unexposed subjects were matched to the exposed subjects by age using a random computer matching technique and were assigned the same start time as the matched exposed subject.
The original cohorts that included subjects aged 50 to 79 were then subdivided into two groups: ages 50 to 54 and 55 to 79 years.
The older group more closely matched the age of the RCT, and the 50-to 54-year-old group encompassed a younger cohort than the RCT. Two different types of analytics were employed to assess outcomes of the database studies. In the first type, analyses were performed using a simulated intention-to-treat analysis where a fixed end time was set and subjects were followed until they dropped out of the database, died, or reached a predetermined end time. In the second type, an as-treated analysis was performed where, in addition to the above criteria, the subject's study ended if the post-menopausal drug treatment was altered.
The database study outcomes' hazard ratios (HRs) were analyzed using Cox-unadjusted and Cox-adjusted results and compared with the RCT event results. Database results also were analyzed using the PERR method to overcome unrecognized confounding, and these results for stroke and acute myocardial infarction were compared with both the Cox-adjusted and the RCT results. 7 Prior Event Rate adjustment compared outcomes before study entry, when neither the exposed nor the unexposed cohorts were taking medications. Theoretically, this should delineate the aggregate effect of all confounders (both measured and unmeasured) on an outcome. Dividing the HR of an outcome during the study by the PERR HR should the result in a value similar to the Cox adjusted HR if there is no unmeasured confounding. The validity of this approach has been substantiated by comparisons of database and RCT outcome results and also by theoretical analyses of the method. 8, 9 Mortality cannot be examined by this method, because death prior to study entry would eliminate entry into the study.
A new method (PTERR) was developed to address unmeasured confounding of mortality of the death rate after the treatment interval in a fashion similar to the PERR use of the outcome rate prior to study. 10 Our prior database studies were used to test the validity of this method. This strategy was feasible because all database studies were analyzed using both "intention-to-treat" and "as-treated" analyses.
Since the "intention-to-treat" analysis often had a duration longer than the "as-treated" analysis, a post-treatment time period could be delineated for the exposed cohort. Because the unexposed cohort subjects were matched by start time to the exposed subjects, their duration could be altered similar to the matched subjects comparison of a similar "post-treatment" period. As noted in the published manuscript, this new method appears to yield valid results, albeit that it could not be verified with the same rigor as the PERR method. 10 One of the prior studies evaluated by this method was the database replication of the WHI RCT. 4 The striking results for mortality in this analysis led to publication of this manuscript. We designed the database mortality results to be for the same age groups as the WHI secondary study, which encompassed women 50 to 60 and 50 to 70 years of age.
| SUMMARY OF METHODOLOGIES DEVELOPED
• PERR analysis is a tool we developed to identify and quantitate unrecognized confounding for many outcomes; it involves analysis of outcomes in the time period preceding the therapy period and is then applied to the data during the analytic period.
• PTERR analysis is a tool we developed specifically to identify and quantitate unrecognized confounding for the death outcome, applying an approach analogous to PERR analysis, but for the post-treatment period.
| RESULTS
The comparisons between the RCT intact uterus and hysterectomy studies and the database PTERR correction results for these studies are shown in Table 1 . The details regarding the death analysis of the database studies are shown in Table 2 . The results for mortality from the WHI RCT intact uterus and hysterectomy studies were compared with database study results of women in the same age brackets The intact uterus and hysterectomy results for the WHI RCT for the 50-to 70-year-old cohorts did not exhibit a decrease in mortality.
By contrast, the results for this age group in both the database studies exhibited a significant decrease in mortality that was also significantly lower than the results in the RCT study. It is important to note that the size of the cohorts in the database studies was dramatically higher than the secondary RCT studies.
In our prior publication, death was decreased significantly in both older (55-79) and younger (50-54) women in both the intact uterus study (estrogen and progesterone) and the hysterectomy study (estrogen only). 7 There was a hint, however, that cohorts without missing data on baseline confounders (BMI, SBP, and smoking) did not exhibit as large a decrease in death. We revisited this issue using our current data on death using cohorts from both the intact uterus and also hysterectomy cohorts. These studies were performed on subjects aged 50 to 70 with no missing confounders. The results for these "no missing" studies are shown in Table 3 . In comparison with the results of the studies with missing data on baseline confounders shown in Table 2, there are no meaningful differences.
| DISCUSSION
Our replication of the WHI RCT provides a deeper insight to support the striking decrease in mortality for women treated with estrogen hormone replacement therapy during menopause. Estrogen is clearly identified as the medication responsible for this effect, since women who ingested both estrogen and progesterone exhibited decreases in mortality similar to those who ingested only estrogen.
The methods utilized aimed to address the potential for unrecognized confounding. Such an approach can be compared with other previous studies. For instance, the secondary subgroup analysis of the WHI RCT tends to support this finding, but the cohorts were too small to achieve statistically meaningful results and also suffer from the possibility of unrecognized confounding. 1 The meta-analysis by Salpeter and colleagues found a decrease in mortality in women with the mean age of <60 years, but not in older women. Furthermore, it does not identify estrogen as the protective medication and also is subject to unrecognized confounding. 11 Mikkola et al used data from the nationwide reimbursement register and the Cause of Death
Register of Finland for their studies of post-menopausal hormone therapy. 12 They reported a decrease in death from treatment with estradiol and/or progesterone treatment along with a decrease in coronary heart disease, stroke, or other causes of mortality. However, this database study did directly not address the possibility of unrecognized confounding.
How post-menopausal estrogen accounts for the prevention of death is not delineated by our study. Both the WHI RCT and our database study examined other outcomes that can provide some clue as to potential ways in which estrogen can protect against death. Both the RCT and the database study found an increase in stroke, no reduction in acute myocardial infarction, an increase in breast cancer, and an increase in events related to venous clotting in subjects treated with estrogen. Estrogen did result in a decrease in colon cancer and also a decrease in hip fracture, but the degree of protection seems unlikely to have resulted in the magnitude of the decline in mortality.
Thus, the basis for the protective effect of estrogen therapy remains unexplained. Nevertheless, our findings strongly support the use of post-menopausal estrogen therapy.
More generally, this work demonstrates the potential of the PTERR analysis method, building upon the PERR analysis method, to help illuminate valid and trustworthy lessons that can be learned from real-world health data derived from properly constructed medical databases. Doing so promises to stimulate further discussion of and research into methodologies grounded in the scientific integrity Core
Value of LHSs, that is so paramount to building trustworthiness and engendering trust in the lessons learned in LHSs aimed at improving health, as well as in the LHSs themselves.
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